Lite Strategy LITS
NASDAQ LITS
$1.06 +0.00 (+0.00%)
At close: Sep 10, 2026 · 4:00 PM EDT

Lite Strategy (LITS) Net Shares Issued and Repurchased (2011 - 2025)

Lite Strategy (LITS) posted Net Shares Issued and Repurchased of $488065.0 for Q2 2025, up 109.0% on a QoQ basis from $233528.0 in Q3 2024, and down 99.83% year-over-year from $290.4 million in Q2 2024.

Analysis

Lite Strategy (LITS) Net Shares Issued and Repurchased (2011 - 2025) Analysis & Trends

Lite Strategy has reported Net Shares Issued and Repurchased for 13 years, with the latest figure at $488065.0 in Q2 2025.

  • On a quarterly basis, Net Shares Issued and Repurchased fell 99.83% year-over-year to $488065.0 in Q2 2025; TTM through Jun 2025 was $488065.0, a 99.83% decrease from a year earlier, with the FY2025 full-year figure at $488065.0, down 99.83% from the prior year.
  • Net Shares Issued and Repurchased was $488065.0 for Q2 2025 at Lite Strategy, up from $233528.0 in the prior quarter.
  • The five-year high for Net Shares Issued and Repurchased was $7.1 billion in Q2 2022, with the low at $227037.0 in Q3 2023.
  • Average Net Shares Issued and Repurchased over 5 years is $928.5 million, with a median of $2.9 million recorded in 2021.
  • The sharpest annual moves came in 2022 and 2023: Net Shares Issued and Repurchased surged 114790.97% in 2022, then sank 99.99% in 2023.
  • Over 5 years, Net Shares Issued and Repurchased stood at $5.1 million in 2021, then surged by 140944.74% to $7.1 billion in 2022, then plunged by 100.0% to $227037.0 in 2023, then climbed by 2.86% to $233528.0 in 2024, then soared by 109.0% to $488065.0 in 2025.
  • The last three Net Shares Issued and Repurchased figures came in at $488065.0 (Q2 2025), $233528.0 (Q3 2024), and $290.4 million (Q2 2024), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Shares Issued and Repurchased (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn -
2 Gilead Sciences 179.97 Bn 176.79 Bn 6.22 Bn -
3 Vertex Pharmaceuticals 130.57 Bn 122.72 Bn 2.84 Bn -
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn -
5 Argenx Se 60.34 Bn 55.16 Bn 1.37 Bn -
6 Moderna 54.37 Bn 49.23 Bn 52.00 Mn -
7 Alnylam Pharmaceuticals 33.07 Bn 29.76 Bn 992.69 Mn -
8 Biogen 31.84 Bn 30.55 Bn 1.96 Bn -
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn -
10 Lite Strategy 38.03 Mn 30.49 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2025 488,065.00
Sep 30, 2024 233,528.00
Jun 30, 2024 290.44 Mn
Sep 30, 2023 227,037.00
Jun 30, 2023 682,074.00
Jun 30, 2022 7.12 Bn
Sep 30, 2021 5.05 Mn
Jun 30, 2021 6.20 Mn
Sep 30, 2018 2.02 Mn
Jun 30, 2018 2.77 Mn
Sep 30, 2017 1.59 Mn
Jun 30, 2017 1.71 Mn
Sep 30, 2016 1.49 Mn
Jun 30, 2016 1,712.00
Sep 30, 2015 1.19 Mn
Jun 30, 2015 807,697.00
Sep 30, 2014 483,241.00
Jun 30, 2014 568,593.00
Sep 30, 2013 325,355.00
Jun 30, 2013 491,168.00